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ABSTRACT
Introduction Amidst growing consensus that stakeholder 
decision- making during drug development should be 
informed by an understanding of patient preferences, the 
Innovative Medicines Initiative project ‘Patient Preferences 
in Benefit- Risk Assessments during the Drug Life Cycle’ 
(PREFER) is developing evidence- based recommendations 
about how and when patient preferences should be 
integrated into the drug life cycle. This protocol describes 
a PREFER clinical case study which compares two 
preference elicitation methodologies across several 
populations and provides information about benefit–risk 
trade- offs by those at risk of rheumatoid arthritis (RA) for 
preventive interventions.
Methods and analysis This mixed methods study will 
be conducted in three countries (UK, Germany, Romania) 
to assess preferences of (1) first- degree relatives (FDRs) 
of patients with RA and (2) members of the public. Focus 
groups using nominal group techniques (UK) and ranking 
surveys (Germany and Romania) will identify and rank 
key treatment attributes. Focus group transcripts will 
be analysed thematically using the framework method 
and average rank orders calculated. These results will 
inform the treatment attributes to be assessed in a 
survey including a discrete choice experiment (DCE) and 
a probabilistic threshold technique (PTT). The survey will 
also include measures of sociodemographic variables, 
health literacy, numeracy, illness perceptions and beliefs 
about medicines. The survey will be administered to 
(1) 400 FDRs of patients with RA (UK); (2) 100 FDRs of 
patients with RA (Germany); and (3) 1000 members of 
the public in each of UK, Germany and Romania. Logit- 
based approaches will be used to analyse the DCE and 
imputation and interval regression for the PTT.
Ethics and dissemination This study has been approved 
by the London- Hampstead Research Ethics Committee 
(19/LO/0407) and the Ethics Committee of the Friedrich- 
Alexander- Universität Erlangen- Nürnberg (92_17 B). The 
protocol has been approved by the PREFER expert review 
board. The results will be disseminated widely and will 
inform the PREFER recommendations.
INTRODUCTION
There is increasing agreement that decision- 
making by the pharmaceutical industry, 
regulators and health technology assess-
ment bodies throughout the development of 
medical products should be informed by an 
understanding of patient preferences, and 
that guidance on best practice is required.1–4 
This study is a case study for the Innovative 
Medicines Initiative (IMI) project ‘Patient 
Strengths and limitations of this study
 ► This study has been developed by an international, 
multidisciplinary team of academic, clinical, phar-
maceutical industry and patient partners, and pro-
vides an example of a rigorously designed treatment 
preference study that is informative for a range of 
stakeholders.
 ► This study addresses both clinical and method-
ological research objectives, and the findings will 
contribute to both the development of efficient pre-
vention strategies for rheumatoid arthritis (RA) and 
the development of best practice on the integration 
of patient preferences into drug development.
 ► This study involves a substantial sample size across 
several populations, allowing comparison of treat-
ment preferences, psychological variables and so-
ciodemographic information across populations in 
three European countries.
 ► This is the first quantitative study of preferences 
for preventive treatments for RA involving a large 
sample of confirmed, rather than self- reported, 
first- degree relatives of patients with a clinician- 
confirmed diagnosis of RA.
 ► This study recruits first- degree relatives indirectly 
via invitations passed on by patients with a con-
firmed diagnosis of RA and may therefore be open 
to selection bias at both patient and participant level.
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Preferences in Benefit- Risk Assessments during the 
Drug Life Cycle’ (PREFER). PREFER aims to strengthen 
patient- centric decision- making products by developing 
evidence- based recommendations to guide stakeholders 
on how and when patient preference studies should 
inform decision- making.
There are many methodological research questions 
that warrant further study in preference research.5 
PREFER conducted a landscape assessment to identify 
the most important questions and pair them with clinical 
case studies, based on the disease under investigation, 
anticipated sample size and clinical research objectives. 
The results of these studies will inform the development 
of recommendations for conducting preference studies. 
The background to both the clinical and methodological 
questions addressed in the present study is outlined in 
the following sections.
Clinical background
Rheumatoid arthritis (RA) is a common chronic destruc-
tive polyarthritis, affecting approximately 1% of the 
general population.6 7 Typical age of onset is between 40 
and 60 years old, although it can begin at much younger 
and older ages. If untreated, RA causes joint damage and 
disability. RA is associated with significant extra- articular 
manifestations reducing life expectancy by approximately 
10 years.8
It is not currently possible to cure RA and long- term 
treatment is usually required. Available treatments 
include conventional (c), biological (b) and targeted 
synthetic (ts) disease- modifying antirheumatic drugs 
(DMARDs), with varying benefit–risk profiles. The main-
stay of treatment is methotrexate, a relatively inexpensive 
cDMARD to which approximately one- third of patients 
respond well.9 For those who do not respond well to first- 
line treatment, the use of a combination of cDMARDs 
and the addition of more (expensive) bDMARDs may be 
employed. Prolonged use of cDMARDs and bDMARDs is 
associated with considerable risk, including risk of infec-
tion and of lung, liver and haematological toxicity.9
Very early treatment of RA is associated with improved 
outcomes.10 11 There is now an emerging research focus 
on treating ‘at risk’ individuals in the preclinical and 
earliest clinically apparent phases of RA12 13 to assess 
whether a relatively short course of therapy will prevent 
or delay the onset of RA. The European League Against 
Rheumatism (EULAR) recommendations identify termi-
nology to describe groups of participants appropriate 
for prospective trials: individuals without RA having (1) 
genetic risk factors for RA, (2) environmental risk factors 
for RA, (3) systemic autoimmunity associated with RA, 
(4) symptoms without clinical arthritis (arthralgia) or (5) 
unclassified arthritis.14
Two completed15 16 and five ongoing (APIPPRA,17 
ARIAA,18 TREAT EARLIER,19 STAPRA,20 SToPRA21) 
proof- of- concept trials are assessing the effectiveness of 
drugs currently used to treat RA to prevent or delay the 
onset of RA in one or more of these ‘at risk’ groups. Novel 
immune tolerising therapies are also being investigated 
in another IMI project, ‘RheumaTolerance for Cure’.22
While members of the general population have a 
1/100 probability of developing RA, first- degree rela-
tives (FDRs; EULAR ‘at risk’ stages 1–2) of existing 
patients are four times more likely to develop RA in the 
future.23 FDRs are therefore likely candidates for preven-
tive approaches. For example, the SToPRA trial (evalu-
ating the preventive effectiveness of a 12- month course 
of hydroxychloroquine21) is recruiting asymptomatic 
FDRs of patients with RA and individuals attending 
health fairs who are autoantibody- positive (EULAR ‘at 
risk’ stages 1–3).
Understanding the treatment preferences of ‘at risk’ 
groups is especially important in preventive contexts, 
where there is uncertainty regarding treatment effec-
tiveness and safety (as per standard patient preference 
studies), and also the individual’s baseline risk of devel-
oping RA in the future, the timeline for that risk and the 
likely future severity of disease. As prospective studies 
elucidate biomarkers predictive of RA development, risk 
stratification of healthy individuals is increasingly likely 
to facilitate early treatment and preventive interven-
tions.24–26 As prevention research evolves, knowledge of 
the preferences of ‘at risk’ individuals around RA treat-
ments repurposed for prevention and (as yet) hypothet-
ical new ones will be valuable to inform the development 
and regulation of efficient and effective preventive inter-
ventions for RA.
It is also of value to understand treatment preferences 
in the general public who are asked to imagine being at 
an elevated risk of developing RA. The assessment of pref-
erences of FDRs at increased risk of RA and a general 
population that is told to assume an increased risk of RA 
allows for comparisons between groups that are expected 
to vary in their familiarity with and understanding of RA.27 
Public misperceptions around the identity and severity of 
RA are common.28 29
A small number of qualitative studies have explored 
perceptions of preventive intervention for RA,30–33 but 
quantitative evidence is limited.34 A discrete choice 
experiment (DCE) assessing preferences for preven-
tive pharmacological interventions for RA of 288 self- 
reported FDRs recruited via the Amazon Mechanical 
Turk suggested that mode of administration may be an 
important determinant of preventive treatment accept-
ability.35 This finding was echoed in a subsequent study 
that included 30 self- reported FDRs.36 However, a best–
worst scaling pilot study found that the effectiveness and 
risks of preventive treatments were more important than 
mode of administration for a small sample of 34 FDRs 
taking part in a prospective cohort study.37 Further quan-
titative evidence is needed in clinically validated popula-
tions and larger samples. The primary clinical objective 
of this preference study is therefore to establish the pref-
erences of ‘at risk’ individuals (ie, children or siblings of 
confirmed patients with RA) and the general public for 
preventive therapies for RA.
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Methodological background
PREFER has identified a number of methodological 
questions for which evidence is currently lacking. This 
case study will provide evidence to address several meth-
odological questions in line with PREFER strategy. First, 
there is no consensus on which is the best method to 
gather quantitative treatment preference data, and 
multiple techniques ranging from simple ranking exer-
cises to complex, resource- intensive trade- off methods are 
employed. PREFER seeks to assess how similar the results 
of simpler/faster/cheaper methods are compared with 
more rigorous/indepth/expensive preference methods 
involving the same set of treatment attributes. This case 
study will compare preferences for preventive treatments 
elicited by DCE38 and probabilistic threshold technique 
(PTT).39 40
In a typical DCE, respondents are asked to complete 
several ‘choice tasks’. Each consists of choosing between 
two or more alternatives that describe a treatment (or no 
treatment). The description of the treatment is based on 
its characteristics, or ‘attributes’. The individual’s pref-
erence for an alternative can be determined based on 
the values of the levels of the included attributes across 
the choice tasks. PTT has a similar, but simpler choice 
task as the DCE. Rather than varying all attribute levels 
according to an experimental design, individuals choose 
between a reference treatment profile and an alternative 
treatment where only one attribute is improved or made 
worse until the participant changes their choice from one 
profile to the other. The point at which the participant 
switches their choice is the threshold. PTT is simpler in 
that it does not require an experimental design, special-
ised analytical or design software, or complex multivariate 
conditional models. This study will determine the extent 
to which results using the PTT differ from results of the 
relatively complex DCE. The DCE attributes and levels 
will be determined first, and the PTT alternatives will be 
chosen based on the DCE attributes and levels, including 
which attribute to modify. The exact selection and formu-
lation of the attributes included in both choice methods 
will be based on a previous qualitative research phase.
A further PREFER objective is to investigate the relation-
ship between measures of psychological constructs and 
preference heterogeneity. In order to do so, this study will 
assess whether measures of psychological constructs (ie, 
perceived risk, beliefs about medicines, illness percep-
tions) can explain preference heterogeneity, as evidence 
in this area is limited.41 Other measures such as health 
literacy and numeracy might also explain preference 
heterogeneity and could impact preference construction 
(ie, leading to differences in choice consistency, certainty 
and so on)42 and will also be assessed.
The current case study will take place in the same format 
in the UK, Germany and Romania, enabling comparisons 
across countries, thus addressing a further PREFER meth-
odological objective and elucidating the transferability of 
preferences across regions. Finally, as most current inter-
vention trials in individuals at risk of RA are targeting 
patients with early symptoms (eg, joint pain) and elevated 
RA- related autoantibodies, the current case study will ask 
FDR participants to imagine they have started to develop 
joint symptoms and have had blood tests, which indi-
cate that they are at high risk of developing RA within 
2 years. Similarly, members of the general population will 
be asked to imagine the same scenario. This will allow 
assessment of whether the FDRs respond systematically 
differently from members of the general public. This will 
address PREFER questions related to both the generalis-
ability of preferences from one specific population in a 
disease to different populations.
METHODS AND ANALYSIS
This study will consist of two phases. A focus group/inter-
view study using nominal group technique (NGT)43 in 
the UK with confirmatory ranking surveys in Germany 
and Romania will be conducted to explore attributes rele-
vant to decision- making about treatments to prevent RA, 
and inform the selection and definition of attributes to 
be used in a quantitative study. This will be followed by a 
stated preference survey to assess treatment preferences 
of FDRs and the general population (figure 1).
We will employ evidence- based guidelines and best 
practices for study design and conduct, including focus 
groups,44 NGT,43 and for preference study design and 
analysis.45 46
Figure 1 Study flow chart.
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Focus group/interview study
The outcomes of the focus group/interview study will be 
(1) a description of themes that are important consider-
ations for decision- making about preventive treatment 
for RA; and (2) a list of treatment attributes relevant for 
decision- making and their rank order.
We aim to conduct four focus groups: two with FDRs 
and two with the general population in the UK. Each 
focus group will have approximately five to seven respon-
dents. Four focus groups are expected to be sufficient to 
generate attributes since focus groups have been shown 
to yield concept saturation after two to four group discus-
sions.44 All participants will be aged 18 years or older. 
Focus group participants will be offered £20 as an incen-
tive. Focus groups will take place at the University of 
Birmingham, UK.
Members of the general population will be invited 
to the focus group through an advert on community 
message boards and online research recruitment plat-
forms. FDRs will be recruited indirectly, through patients 
with RA identified at outpatient clinics at participating 
sites. Patients with RA attending rheumatology clinic will 
be invited to pass on a study invitation to their FDRs. All 
focus group participants will provide informed consent 
before taking part, facilitated by a participant informa-
tion sheet (PIS).
To increase consistency across focus groups, a semi-
structured interview guide with questions about charac-
teristics that might be expected in a preventive treatment 
for RA will be developed. The guide will be developed 
with clinical expert input and an international panel of 
patient research partners and informed by a review of the 
literature. Any treatment attributes that have featured 
across previous studies of preferences for RA treatments 
that are not identified during the initial discussion will be 
introduced to participants for further discussion. NGT43 
will be used to obtain rankings of attributes identified in 
the focus group by their relative importance to inform 
the preference study design.
We will ask focus group participants to imagine they 
have started to develop joint pain and have had a blood 
test that indicates they have a 40% risk to develop RA in 
the next 2 years. This is representative of participants 
included in current trials of preventive interventions for 
RA, whose risk of developing RA within 2 years is between 
10% and 60% depending on the presence of other risk 
factors.47
The focus group discussions will be audio- recorded 
and transcribed verbatim. The transcripts will be analysed 
using the framework method.48 At least 20% of transcripts 
will be independently coded by multiple researchers to 
develop a coding framework with input from patient 
research partners. At least two researchers will inde-
pendently code each transcript applying the agreed 
framework.
Analysis of transcripts will proceed at the same time 
as data collection. When there is consensus among the 
research team that thematic saturation has been achieved 
and no new treatment attributes are being identified, 
no new focus groups will be scheduled. The original list 
of attributes used for the ranking exercises in the NGT 
will then be included in a ranking survey for FDRs and 
members of the general public in Germany (n=30) and 
members of the general public in Romania (n=30). This 
survey aims to confirm/validate the selection of the 
most important treatment attributes across all countries 
involved in the quantitative study. The attribute rank-
ings and focus groups findings will then be reviewed with 
clinical and methodological experts and patient part-
ners to select those appropriate for inclusion in a DCE, 
and a representative range of levels for each attribute 
will be selected. Any high- ranking attributes that are not 
included in the DCE (eg, because of likely dominance) 
will be included (at a constant level) in the survey choice 
task setting.
Stated preference study
The attributes and levels identified above will be incor-
porated into a survey containing both DCE and PTT. 
Both approaches will assess preferences for RA preven-
tive treatments by asking respondents to choose between 
treatment alternatives. Each treatment will be described 
in terms of its level of each attribute. The order of 
presentation (DCE followed by PTT, or vice versa) will be 
randomised.
The combinations of attribute levels that define each 
profile and the set of profiles in each choice question in 
a DCE are known as the experimental design. The exper-
imental design must have statistical properties that allow 
estimation of the preference weights of interest. This 
study will use Ngene (ChoiceMetrics, Sydney, Australia) to 
construct a Bayesian D- efficient fractional- factorial exper-
imental design.49 Prior information on the importance of 
the attributes will be based on previous literature and best 
guesses for a pilot study, and outcomes of initial analysis 
(conditional logit) of pilot data for the main survey.
Survey instrument
All participants will provide informed consent before 
completing the survey. Respondents will complete a demo-
graphic questionnaire and assess their perceived risk of 
developing RA. They will be asked to read a description of 
RA and risk factors for RA developed with clinical experts 
and patient partners. Respondents will then be asked to 
imagine they have started to develop joint pain and have 
had a blood test that indicates they have an elevated risk 
of developing RA in the next 2 years. This will be followed 
by evaluation questions, including warm- up and knowl-
edge questions, to test participants’ understanding of the 
information presented. For example, the participant may 
be shown a risk grid to test understanding of percentages, 
with 3 persons selected and 97 persons not selected to test 
understanding of 3% or 3 in 100. This will be followed by 
either the DCE/PPT choice task questions, which will be 
preceded by a guided ‘walk through’ demonstration of a 
DCE/PTT choice task and some warm- up questions. To 
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avoid carry- over effects from DCE to PTT or vice versa, 
respondents will then complete the Single Item Literacy 
Screener50 and the three- item version of the Subjective 
Numeracy Scale.51 This will be followed by a guided 
example and evaluation questions for the choice tasks of 
the second method, followed by the actual choice tasks. 
Participants will then complete the Brief Illness Percep-
tion Questionnaire52 53 and the Beliefs about Medicines 
Questionnaire- General.54 On completion of the survey, 
participants will be provided with sources of additional 
information about RA and risk factors for RA.
The survey will be pretested in a convenience sample 
(n=15) using qualitative think aloud interviews. These 
participants will be paid £20/€20 in shopping vouchers. 
To inform the final experimental design and optimise 
statistical efficiency, a survey pilot will be conducted with 
100 members of the general public in the UK.
Survey sample
We aim to recruit a total of 3500 participants who have 
not received a diagnosis of RA, including the following:
 ► 400 adults who are FDRs of an individual with a 
confirmed diagnosis of RA, UK.
 ► 100 adults who are FDRs of an individual with a 
confirmed diagnosis of RA, Germany.
 ► 1000 adults from the general population, UK survey 
panel.
 ► 1000 adults from the general population, Germany 
survey panel.
 ► 1000 adults from the general population, Romania 
survey panel.
All participants will be asked to assume an increased 
risk of developing RA in the next 2 years.
A priori sample size calculations represent a chal-
lenge in DCE experiments. Most published studies 
have a sample size of 100–300 respondents.55 However, 
the minimum sample size depends on several criteria, 
including question format, choice task complexity, 
desired precision of results and subgroup analyses.46 56 A 
method for computing sample size was proposed by de 
Bekker- Grob et al57; however, as the article highlights, 
there is no analytical solution or power calculation that 
can be used to determine the appropriate sample size for 
a DCE unless enough information to inform the selection 
of priors exists.
There is no specific power calculation to determine 
sample size in PTT studies without knowing the expected 
threshold value a priori. Most PTT studies are conducted 
with 100 or fewer respondents, and substantially smaller 
samples (between 20 and 42 respondents) have been 
used successfully in previous studies.57–60 Given the lack 
of clear guidance on sample size estimation for PTT, 
we assume that a minimum sample size of 50 per PTT 
choice set would be needed to estimate a threshold value 
in each threshold exercise. To account for potential 
heterogeneity, a minimum total sample size of 100 will be 
considered sufficient to answer the primary objective. A 
target sample size of 200 is sufficient for the purposes of 
conducting subgroup analyses.
A sample of 250 FDRs should provide enough infor-
mation to address the key clinical research objective 
with acceptable precision.55 An increased sample size of 
400 will allow increased precision of estimates for other 
comparisons. Based on the sample size requirements for 
both methods and accounting for the number of addi-
tional methodological research questions this study antic-
ipates to answer, a sample size of 1000 from a general 
population panel in each country should provide enough 
information to enable comparisons across groups and 
methods with acceptable precision.
Sample identification and eligibility
FDRs will be recruited through patients with a confirmed 
diagnosis of RA identified via rheumatology clinics. A 
letter explaining the study and requesting that patients 
invite an FDR to participate in the study will be given to 
patients during routine appointments or via mail. This 
letter will include a study invitation and PIS to pass on to 
an FDR. The invitation will contain a link to the online 
survey. The first section of the survey will be the PIS and 
online consent form. FDR survey participants will be 
offered an incentive (£5/€5 online gift voucher).
The general population samples will be recruited 
though online survey panels. Potential respondents will 
receive an email survey invite with a unique password- 
protected link to the online survey. The general popu-
lation sample composition will match the expected FDR 
sample in terms of age and gender. The initial questions 
of the survey will be used to confirm the respondent’s 
eligibility. Eligible respondents will be provided the PIS 
and asked to provide anonymous electronic informed 
consent to participate. After completing the survey, panel 
members will be credited with panel points (equivalent to 
approximately €2–3 for a 30 min online survey).
Statistical considerations and data analysis
The main outcomes of the stated preference study will be 
the (1) relative preference weights for levels of treatment 
attributes; (2) estimated risk equivalents (maximum 
acceptable risk (MAR) and minimum acceptable benefit 
(MAB)) for changes in treatment attributes; and (3) 
potential treatment shares.
For the DCE, a logit- based analysis strategy will be 
conducted to estimate preferences for attributes of RA 
prevention therapies, including random parameters 
logit (RPL) modelling and latent class analyses (LCA). 
Final decisions on the modelling procedure will be 
made once data collection has been completed. This 
decision will be based on model fit and clinical interpre-
tive values. Different models might be used to answer 
the different research questions in this case study. PTT 
data will be analysed using imputation and interval 
regression. The MAR/MAB values for benefits and risks 
will be calculated and allow comparison between DCE 
and PTT methods. Heterogeneity of preferences and 
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the impact of participant characteristics (eg, demo-
graphics, RA knowledge, psychological instruments) 
will be investigated by applying appropriate statistical 
models including LCA for the DCE and/or subgroup 
analyses for the DCE (RPL) and PTT methods. For the 
DCE, only the potential treatment shares of currently 
existing preventive treatment will be calculated. All 
results described above will be formally compared 
between the three countries and between FDRs and the 
general population.
The results of the DCE and PTT will be compared 
qualitatively and quantitatively. From a quantitative 
perspective, the MAR and/or MAB will be calculated 
using each method for a particular benefit and risk 
attribute over the same range. This allows the average 
MAR/MAB value and associated 95% CIs to be directly 
compared. Next, the conditional relative importance 
of the benefits and harms will be compared across 
methods. As these methods would evaluate heteroge-
neity somewhat differently (DCE using LCA/RPL vs 
PTT categorising individual preferences), the compar-
ison of heterogeneity of preferences will be qualitative. 
The extent to which DCE and PTT results would result 
in different decisions will be assessed using interviews 
with stakeholders. Additionally, comparisons will be 
made regarding logistics of both methods with respect 
to budget, time and perceived cognitive load (based on 
evaluation questions after each method).
Patient and public involvement
Patient partners in previous projects highlighted the 
importance of the clinical objectives of this study. Seven 
patient research partners provide input on all aspects 
of this study, including development of methodological 
objectives, choice of methods, recruitment procedures, 
study documents, focus group discussion guide, selec-
tion of attributes and levels, selection of psychological 
measures, survey design and content, interpretation of 
results, and public dissemination of project findings.
ETHICS AND DISSEMINATION
Ethical considerations
It is possible (though unlikely61) that participants and 
patients approached to recruit FDRs might be concerned 
by the prospect of an enhanced risk of developing RA. 
We will provide participants with an information booklet 
developed as part of the EuroTEAM project62 and which 
discusses issues around being at risk of RA. English and 
German versions are currently available. Sources of 
further information and contact details for support will 
also be provided.
We will ensure that focus group participants are iden-
tified by a participant number, not by name, on both 
audio recordings and transcripts to protect their privacy. 
All survey responses are anonymous. FDRs who complete 
the survey and wish to receive payment will be directed to 
an independent landing page so they can provide email 
addresses to facilitate payment without the addresses 
being linked to survey responses.
Regulatory and protocol compliance
This study has been approved by the London- Hampstead 
Research Ethics Committee (19/LO/0407) and the 
Ethics Committee of the Friedrich- Alexander- Universität 
Erlangen- Nürnberg (92_17 B). The protocol has also 
been reviewed and approved by the PREFER expert 
review board and steering committee. The study will be 
conducted in compliance with this protocol, guidelines 
for Good Clinical Practice, the Research Governance 
Framework for Health and Social Care, and the Data 
Protection Act 1998. Personal data protection in this 
study will be compliant with the European Union General 
Data Protection Regulation 2016/679 and the Informa-
tion Security Policies of the Universities of Birmingham 
and Erlangen.
Publication and dissemination policy
Publication of study results will be shared with patient 
organisations as lay summaries and submitted to peer- 
reviewed journals in accordance with the PREFER consor-
tium agreement and the International Committee of 
Medical Journal Editors recommendations.63
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